Denmark Pharmaceutical Market Trends

In Denmark, prescriptions are not covered under public health insurance. However, the national scheme does reimburse the partial costs of some medications. Also, in Denmark, the direct-to-consumer advertising of prescription drugs is permitted under strict legislation. This positively impacts the market as most pharmacists and end users will be well aware of new or present medications available for the treatment of diseases. Prescription drug sales have increased compared to previous years owing to the rising chronic disease. For instance, according to an article published by ScienceDirect, in July 2021, more than 11,500 abdominal cancers are diagnosed yearly in Denmark. Thus, the increased prevalence of chronic diseases is expected to drive growth in the market.​

Significant competitors in the prescription drug market are making substantial advancements for the unmet requirement that exists in the market space as a result of the rising prevalence of chronic diseases in this area. For instance, in April 2022, the Danish Parliament adopted a bill to introduce a new 4-year pilot program on reimbursement of medicines based on shared risks. The pilot program allows the Danish Medicines Agency to grant general conditional reimbursement of prescription-only medicines based on shared risks. Similarly, the world's largest diabetic manufacturer, Novo Nordisk, bought Corvidia Therapeutics from AstraZeneca in June 2020 for an initial USD 725 million to diversify into cardiovascular disease medicines in the Danish market. Thus, the above-mentioned factors are expected to increase the market growth.